Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Garassino presents 5-year results from the EMPOWER-Lung 1 trial, discussing cemiplimab monotherapy's long-term survival benefits in advanced NSCLC patients with PD-L1 expression ≥50%.

Cemiplimab Monotherapy for First Line Advanced NSCLC Patients With PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung